MarketReader
MarketReader software gives investors a new kind of tool to comprehend the market in real-time, arrive at data-driven explanations of asset price movement, and invest as a result. Its software offers clear, objective explanations of asset price movement in a way that is accessible to different types of investors, from retail to institutional.
$3.10M
Latest Funding
Seed
Latest Funding Stage
2023-01-18
Funding Date
9
Employees
United States
Location
New York, New York
City & State
Key Contacts
Open Positions
View Careers PageSimilar Startups
EvidenceHunt
EvidenceHunt is an AI-powered research assistant developed by medical professionals for healthcare research. Our focus is on delivering tools that streamline gathering and analyzing clinical evidence. With features like AI Chat for interactive queries and comprehensive Direct Search options, EvidenceHunt allows precise data retrieval andanalysis.
Augury
Augury helps eliminate downtime, reduce maintenance costs and maximize productivity for critical machines in industrial and commercial applications ranging from bottling and food processing to paper products and pharmaceuticals. Its Machine Health solutions combine advanced sensors with powerful AI capabilities and collaboration tools to help teams understand when machines are at risk.
Sawmills
Sawmills is the first AI-powered telemetry management platform, enabling enterprises to optimize observability costs while improving data quality and reliability. Built on OpenTelemetry, Sawmills leverages advanced AI to analyze and refine telemetry data in real-time, preventing system outages and unexpected cost spikes.
BEKhealth
BEKhealth harnesses its AI-powered chart abstraction and patient-matching platform to help organizations conducting clinical trials and observational studies better understand their patient populations, optimize feasibility, speed up site selection, and rapidly identify clinically qualified participants by extracting structured and unstructureddata from electronic medical records (EMRs) that captures three times more trial criteria.